New

Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now

You have successfully sign out
Loading...
Shape
Mangoceuticals, Inc.
MGRX
Shape
US Flag

NASDAQ

Unprofitable

EPS improving

Unprofitable

EPS improving

6M

Medical - Healthcare Information Services

Next Earning date - 25 Oct 2024

6M

Medical - Healthcare Information Services

Next Earning date - 25 Oct 2024

0.21USD
Shape-0.01 ( -6.36%)
favorite-chart

Relative Strenght

96
favorite-chart

Volume Buzz

-78%
favorite-chart

Earning Acce

Yes
favorite-chart

Dist 52w H.

82%
OverviewChart

Quote Panel

Shape
Updated October 12, 2024
1W -5.37 % 1M -23.70 % 3M -46.60 % 1Y -67.81 %

Key Metrics

Shape

  • Market Cap

    6.16M

  • Shares Outstanding

    29.91M

  • Share in Float

    19.06M

  • Dividende

    0

  • Earning Date

    25 Oct 2024

  • Price Target

    0.206

  • Average Volume

    4.11M

  • Beta

    0

  • Range

    0.143-1.12

  • Industry

    Medical - Healthcare Information Services

  • Website

    https://www.mangorx.com

  • Sector

    Healthcare

Fundamentals

Shape

N/A

P/E Ratio

7.11x

P/S Ratio

0.36x

P/B Ratio

0.0

Debt/Equity

-1052.9%

Net Margin

$-0.4

EPS

How MGRX compares to sector?

P/E Ratio

MGRX

-1x

FOXO 0x
ETAO -6x
HCTI 0x
SNCE -5x
BFRG -4x

Relative Strength

Shape

MGRX

Sector

loading...

Top 5 RS in Group

Symbol

Company

RS

5-Day Perf.

Forecast

Shape

No Data Available

Analyst rating

No Data Available

Last analyst upgrade/downgrade

No Data Available

Earnings GrowthShape

status-upYoY

Current

Estimates

Q4.22

arrow
arrow

N/A

-0.04
vs -0.00

Q1.23

arrow
arrow

N/A

-0.23
vs -0.00

Q2.23

arrow
arrow

N/A

-0.14
vs -0.01

Q3.23

arrow
arrow

N/A

-0.11
vs -0.10

Q4.23

arrow
arrow

N/A

-0.13
vs -0.04

Q1.24

arrow
arrow

N/A

-0.10
vs -0.23

Q2.24

arrow
arrow

N/A

-0.09
vs -0.14

Sales GrowthShape

status-upYoY

Current

Estimates

Q4.22

arrow
arrow

NA

8.9K  vs NA

Q1.23

arrow
arrow

NA

100.7K  vs NA

Q2.23

arrow
arrow

NA

141.2K  vs NA

Q3.23

arrow
arrow

NA

245.2K  vs NA

Q4.23

arrow
arrow

+2634%

244.4K  vs 8.9K

Q1.24

arrow
arrow

+113%

214.1K  vs 100.7K

Q2.24

arrow
arrow

+16%

163.2K  vs 141.2K

Return on EquityShape

status-upQoQ

Q3.22

arrow
arrow

-118%

-1.18
vs 2.38

Q4.22

arrow
arrow

-110%

-1.10
vs -1.18

Q1.23

arrow
arrow

-67%

-0.67
vs -1.10

Q2.23

arrow
arrow

-76%

-0.76
vs -0.67

Q3.23

arrow
arrow

-133%

-1.33
vs -0.76

Q4.23

arrow
arrow

-331%

-3.31
vs -1.33

Q1.24

arrow
arrow

+247%

2.47
vs -3.31

Q2.24

arrow
arrow

-16%

-0.16
vs 2.47

Institutionnal OwnershipShape

status-up

Earnings Growth

Latest News

MGRX

globenewswire.com

7 hours ago

MangoRx Addresses $49.3 Billion Global GLP-1 Market With Launch of Oral Semaglutide for Advanced Weight Loss Treatment
MGRX

globenewswire.com

8 hours ago

MangoRx Introduces Oral Tirzepatide GLP-1 Receptor Agonist for Advanced Weight Loss Solutions
MGRX

globenewswire.com

8 hours ago

MangoRx Completes Migration to DEA-Approved Telemedicine Platform, Accelerating Timeline of Oral Dissolvable GLP-1 Weight Loss Treatments Featuring Semaglutide and Tirzepatide
MGRX

accesswire.com

8 hours ago

MangoRx Receives Request for Proposal (RFP) From ISFLST for New Male Enhancement Product Exclusive for the Asian Market
MGRX

globenewswire.com

9 hours ago

MangoRx Reports 1,685% Increase in Shareholders' Equity From December 31, 2023, to $13.8MM, and 56% Increase in Year-Over-Year Revenue for First Half of 2024
MGRX

globenewswire.com

17 hours ago

MANGOCEUTICALS, INC. ANNOUNCES 1-FOR 15 REVERSE STOCK SPLIT AS PART OF NASDAQ COMPLIANCE PLAN

New Feature Coming Soon, Stay Tuned!

ShapeShape